Recent News

• 03.19.2026 - Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights
• 12.08.2025 - Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Recurrent Genital Herpes
• 11.10.2025 - Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates
• 11.07.2025 - Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting®
• 10.14.2025 - Assembly Biosciences Announces Upcoming Investor Conference Participation

Recent Filings

• 03.19.2026 - S-3 Registration statement under Securities Act of 1933
• 03.19.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 03.19.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.19.2026 - 8-K Current report
• 03.19.2026 - EX-99.1 EX-99.1
• 02.09.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 12.08.2025 - 8-K Current report
• 12.08.2025 - EX-99.1 EX-99.1
• 12.08.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 11.21.2025 - EFFECT Notice of Effectiveness